Calistoga banks $40M Series C for pivotal trial work

Seattle-based Calistoga Pharmaceuticals--a 2009 Fierce 15 company--has banked a $40 million venture round, bringing its four-year take to $100 million. The money will be used to further its lead drug, CAL-101, which throttles cancer cell growth, while pushing another therapy for rheumatoid arthritis and asthma into a mid-stage trial. Calistoga is focused on a niche of the hot PI3 kinase inhibitor space: delta isoform-selective PI3 inhibitors. The developer has two clinical stage programs with...